The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).
Neil M. Iyengar
No relevant relationships to disclose
Monica Nancy Fornier
No relevant relationships to disclose
Steven Sugarman
No relevant relationships to disclose
Maria Theodoulou
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Tiffany A. Troso-Sandoval
No relevant relationships to disclose
Gabriella D'Andrea
No relevant relationships to disclose
Pamela Drullinsky
No relevant relationships to disclose
Julie Fasano
No relevant relationships to disclose
Devika Gajria
No relevant relationships to disclose
Shari Beth Goldfarb
No relevant relationships to disclose
Elizabeth Anne Comen
No relevant relationships to disclose
Diana Lake
No relevant relationships to disclose
Shanu Modi
No relevant relationships to disclose
Tiffany A. Traina
No relevant relationships to disclose
Melanie Chen
No relevant relationships to disclose
Sujata Patil
No relevant relationships to disclose
Jose Baselga
No relevant relationships to disclose
Larry Norton
No relevant relationships to disclose
Clifford A. Hudis
No relevant relationships to disclose
Chau T. Dang
Research Funding - GlaxoSmithKline